Mesenchymal stromal cells in complex anti-inflammatory therapy of ulcerative colitisL.B.

L B Labeznik; O V Knyazev; A G Konoplyannikov; A I Parfyenov; P L Scherbakov; V E Sagynbaeva

doi:10.23868/gc121697

Genes & Cells ›› 2011, Vol. 6 ›› Issue (4) : 95 -103. DOI: 10.23868/gc121697

Articles

other

Mesenchymal stromal cells in complex anti-inflammatory therapy of ulcerative colitisL.B.

Author information +

Central Research Institute of Gastroenterology of the Moscow Department of Public Health

Medical Radiology Research Center of the RF Ministry of Public Health and Social Department, Obninsk

Central Research Institute of Gastroenterology of the Moscow Department of Public Health

Medical Radiology Research Center of the RF Ministry of Public Health and Social Department, Obninsk

Central Research Institute of Gastroenterology of the Moscow Department of Public Health

Show less

History +

PDF

Cite this article

Download citation ▾

L B Labeznik, O V Knyazev, A G Konoplyannikov, A I Parfyenov, P L Scherbakov, V E Sagynbaeva. Mesenchymal stromal cells in complex anti-inflammatory therapy of ulcerative colitisL.B.. Genes & Cells, 2011, 6(4): 95-103 DOI:10.23868/gc121697

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Kappelman M.D., Rifas-Shiman S.L., Kleinman K. et al. The prevalence and geographic distribution of Crohns disease and ulcerative colitis in the United States. Clin. Gastroenterol. Hepatol. 2007; 5: 1424-9.

[2]	Loftus E.V. The burden of inflammatory bowel disease in the United States: a moving target? Clin. Gastroenterol. Hepatol. 2007; 5: 1383-4.

[3]	Arthur A., Zannettino A., Gronthos S. The therapeutic applications of multipotential mesenchymal stromal stem cells in skeletal tissue repair. J. Cell Physiol. 2009; 218: 237-45.

[4]	Mishra P.K., Singh S.R., Joshua I.G. et al. Stem cells as a therapeutic target for diabetes. Front Biosc. 2010; 15: 461-77.

[5]	Wayne G. Overview of stem cell therapy for Crohns disease. Expert Opin. Biol. Ther. 2009; 9(7): 841-7.

[6]	Brittan M., Alison M.R., Schier S. et al. Bone marrow stem cell-mediated regeneration in IBD: where do we go from here? Gastroenterology 2007; 132:1171-3.

[7]	Лазебник Л.Б., Коноплянников А.Г., Князев О.В. и др. Ис- пользование аллогенных мезенхимальных стромальных клеток костномозгового происхождения в лечении воспалительных забо- леваний кишечника. Терапевтический архив 2010; 2(82): 38-43.

[8]	Rachmilevitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br. Med. 1989; 298: 82-6.

[9]	Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalcylic acid therapy for mildly to moderately active ulcerative colitis. N. Eng. J. Med. 1987; 317(26): 1625-9.

[10]	Geboes K., Riddel R., Jensfelt B. et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000; 47: 404-9.

[11]	Sandborn W.J, Feagan В.G., Hanauer S.В. et al. А review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122: 512-30.

[12]	Цыб А.Ф., Коноплянников А.Г., Колесникова А.И. и др. Получение и использование в медицине клеточных культур из ме- зенхимальных стволовых клеток костного мозга человека. Вестник РАМН 2004; 59(9): 71-6.

[13]	Oyama Y., Traynor A.E., Barr W. et al. Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens. Bone Marrow Transplant. 2003; 32 Suppl 1: S81-3.

[14]	Румянцев П.П. Кардиомиоциты в процессах репродукции, дифференцировки и регенерации. Л.: Наука; 1982.

[15]	Полежаев Л. В. Регенерация. М.; 1977.

[16]	Banerjee M., Kumar A., Bhonde R.R. Reversal of experimental diabetes by multiple bone marrow transplantation. Biochem. Biophys. Res. Commun. 2005; 328(1): 318-25.

[17]	Zangi L., Margalit R., Reich-Zeliger S. et al. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells 2009; 27(11): 2865-74.

[18]	Lee R., Pulin A., Seo M. et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5: 54-63.

[19]	Morigi M., Imberti B., Zoja C. et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J. Am. Soc. Nephrol. 2004; 15: 1794-804.

[20]	Toma C., Pittenger M., Cahill K. et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circ. Res. 2002; 105: 93-8.

[21]	Francois S., Bensidhoum M., Mouiseddine M. et al. Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells 2006; 24:1020-9.

[22]	Schrepfer S., Deuse T., Reichenspurner H. et al. Stem cell transplantation: the lung barrier. Transplant. Proc. 2007; 39:573-6.

[23]	Gao J., Dennis J., Muzic R. et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs. 2001; 169: 12-20.

[24]	Sjoholm I., Edman P. Acrylic microspheres in vivo. I. Distribution and elimination of polyacrylamidemicroparticles after intravenous and intraperitoneal injection inmouse and rat. J. Pharmacol. Exp. Ther. 1979; 211:656-62.